Boothbay Fund Management LLC Acquires 276,345 Shares of Maze Therapeutics, Inc. $MAZE

Boothbay Fund Management LLC grew its holdings in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 365.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 351,875 shares of the company’s stock after purchasing an additional 276,345 shares during the period. Boothbay Fund Management LLC owned about 0.73% of Maze Therapeutics worth $9,124,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in MAZE. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter. Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Maze Therapeutics during the 3rd quarter worth $52,000. Legal & General Group Plc raised its holdings in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after acquiring an additional 3,371 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after acquiring an additional 3,774 shares in the last quarter.

Wall Street Analyst Weigh In

MAZE has been the topic of several analyst reports. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. Finally, Guggenheim upped their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $54.63.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $50.21 on Friday. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $52.86. The stock has a market capitalization of $2.42 billion, a P/E ratio of -2.40 and a beta of 4.47. The stock has a fifty day moving average of $44.82 and a 200-day moving average of $35.75.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Atul Dandekar sold 72,400 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. The trade was a 87.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 230,000 shares of company stock worth $9,768,292 over the last 90 days.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.